| Bioactivity | LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor in T cells with an IC50 of 508 nM. LTV-1 has the potential for autoimmunity treatment[1]. | ||||||||||||
| Target | IC50: 508 nM (LYP, in T cells) | ||||||||||||
| Invitro | LTV-1 (1.25-40 μM) has no notable effect on cell viability (metabolic rate assay), even at the highest concentration tested (40 μM). Thus, LTV-1 is not cytotoxic in HeLa cells, Jurkat TAg T cells and peripheral blood mononuclear cells (PBMC)[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | LTV-1 | ||||||||||||
| CAS | 347379-29-7 | ||||||||||||
| Formula | C26H20N2O5S | ||||||||||||
| Molar Mass | 472.51 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Vang T, et al. LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol. 2012 Mar 18;8(5):437-446. |